Therefore, GLUT inhibitors have been used in a variety of combinations with chemotherapeutics, such as doxorubicin, paclitaxel, and cytarabine, and they exhibit synergistic or additive cancer-fighting effects with reduced chemo-, radio-, and immuno-resistance. Here, SLC2A1 is linked to cancer.